AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29180524
Drug: Omadacycline 450
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omadacycline 450 mg
Trial: 29180524
Drug: Omadacycline 600
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omadacycline 600 mg
Trial: 20669674
Drug: TXLC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXLC + aspirin
Trial: 17721640
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of conventional knee and hip oriented rehabilitation programs
Trial: 15730802
Drug: Rehabilitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation group (routine treatment and early rehabilitation for 28 days, followed by community rehabilitation for 6 months or specialized reinforcement training for 2 months)
Trial: 15730802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment and early rehabilitation for 28 days, followed by self-conducted rehabilitation training for 6 months)
Trial: 11558795
Drug: Low CSF
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low CSF hypocretin levels (<100 pg/ml) in 32 of 38 patients (all HLA-positive)
Trial: 9778000
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg propofol intravenously (group 2)
Trial: 7873494
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of activated autologous peripheral blood lymphocytes (after cultivation with anti-CD3 antibody and IL-2)
Trial: 29743098
Drug: HFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC at 30 l/min and 31 °C
Trial: 29743098
Drug: HFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC at 60 l/min and 31 °C
Trial: 29743098
Drug: HFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC at 60 l/min and 31 °C in patients with clinical FiO2 ≥ 45%
Trial: 29743098
Drug: HFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC at 30 l/min and 37 °C
Trial: 29743098
Drug: HFNC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC at 60 l/min and 37 °C
Trial: 24587110
Drug: Other treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatment approaches (including reading fluency trainings, phonemic awareness instructions, reading comprehension trainings, auditory trainings, medical treatments, interventions with coloured overlays or lenses, sunflower therapy, motor exercises)
Trial: 20950476
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg AMG 108
Trial: 20950476
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg AMG 108
Trial: 20950476
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg AMG 108
Trial: 1827096
Drug: Clarithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (250 mg twice daily)
Trial: 1827096
Drug: Roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (150 mg twice daily)
Trial: 30979666
Drug: Psychosocial health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial health promotion intervention (manual‐based multi‐component health promotion program based on motivational interviewing and cognitive behavioral therapy)
Trial: 27496630
Drug: Conservative transfusion
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative transfusion strategy (RBC transfusion for hemoglobin < 7.0 g/dL for biventricular repairs or < 9.0 g/dL for palliative procedures plus clinical indication)
Trial: 27496630
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (RBC transfusion for hemoglobin < 9.5 g/dL for biventricular repairs or < 12 g/dL for palliative procedures regardless of clinical indication)
Trial: 26561623
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (2.4 g/d) for 4 weeks
Trial: 26561623
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (2.4 g/d) for 4 weeks + aspirin (300 mg/d) during the last 7 days
Trial: 21216507
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of methylcobalamin and 5 mg of folic acid once daily for 24 months
Trial: 8641826
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 24 months
Trial: 17526862
Drug: G-CSF+ group
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF+ group (ATG, CyA, and G-CSF)
Trial: 17526862
Drug: G-CSF- group
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF- group (ATG and CyA)
Trial: 17526862
Drug: G-CSF+ group
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF+ group
Trial: 17526862
Drug: G-CSF- group
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF- group
Trial: 15446640
Drug: Ski lessons
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ski lessons only for two weeks, 2 to 4 hours daily
Trial: 9536157
Drug: Antioxidant supplements
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplements (15 mg beta‐carotene, 75 mg vitamin E, and 650 mg vitamin C) once a day for three months
Trial: 7625474
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day of haloperidol
Trial: 7625474
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of haloperidol
Trial: 7625474
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day of haloperidol
Trial: 2186655
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine 0.1 mg/kg
Trial: 27473350
Drug: ACTH infusion
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH infusion
Trial: 26372487
Drug: 4-week intensive
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week intensive fluconazole treatment for CrAg-positive patients
Trial: 26372487
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (CrAg-negative patients)
Trial: 14669315
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment for 12 months
Trial: 14669315
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment-naïve)
Trial: 1495849
Drug: Oral ribosomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ribosomal vaccine D53
Trial: 1495849
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral ribosomal vaccine D53
Trial: 6716521
Drug: 10-gauge Angiocath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-gauge Angiocath and 8 Fr pulmonary artery introducer catheter with large-bore intravenous tubing (5.0 mm I.D.)
Trial: 6716521
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous tubing (3.2 mm I.D.)
Trial: 12133187
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for sepsis
Trial: 23226426
Drug: Oxaliplatin-based chemotherapy
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin-based chemotherapy + Cetuximab or Panitumumab
Trial: 23226426
Drug: Oxaliplatin-based chemotherapy
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin-based chemotherapy + Cetuximab
Trial: 23226426
Drug: Oxaliplatin-based chemotherapy
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin-based chemotherapy + Anti-EGFR drugs
Trial: 17432692
Drug: Qingjin Runfei
RxNorm normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingjie Shine Mastic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingjin Runfei Decoction (QRD) combined with hormone and antibiotic
Trial: 17432692
Drug: Hormone and
RxNorm normalized name: Parathyroid hormone and/or parathyroid hormone derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone and antibiotic
Trial: 15610365
Drug: Active omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active omega-3 supplemented group (daily tuna fish oil supplement and omega-3-rich margarines and cooking oils)
Trial: 15610365
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo supplement with polyunsaturated margarines and cooking oils)
Trial: 10845823
Drug: High dialysate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dialysate calcium concentration (HdCa; 1.75 mmol/L)
Trial: 10845823
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate calcium concentration (LdCa; 1.25 mmol/L)
Trial: 10845823
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from HdCa to LdCa treatment
Trial: 10845823
Drug: Both LdCa
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both LdCa and HdCa treatment groups
Trial: 9354201
Drug: Omeprazole triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole triple therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, metronidazole 400 mg t.d.s. for the first week)
Trial: 9354201
Drug: Omeprazole dual
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole dual therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, placebo during the first week)
Trial: 9354201
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients treated analysis for omeprazole triple therapy
Trial: 9354201
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients treated analysis for omeprazole dual therapy
Trial: 9354201
Drug: Consultations, investigations,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consultations, investigations, and prescriptions relating to upper gastrointestinal symptoms
Trial: 3545686
Drug: Pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10 to 20 mg per day)
Trial: 3545686
Drug: Pindolol alone
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol alone or in combination with a diuretic
Trial: 24413697
Drug: Post-study caffeine
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-study caffeine administration
Trial: 19448528
Drug: Oral Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive Pills (OCPs)
Trial: 18036290
Drug: Propofol combined
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol combined with low dose fentanyl (Group PF)
Trial: 18036290
Drug: Midazolam combined
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam combined with low dose fentanyl (Group MF)
Trial: 9734883
Drug: Portal-vein infusion
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal-vein infusion (PVI) of fluorouracil (500 mg/m2) plus heparin (5000 IU daily for 7 days)
Trial: 9734883
Drug: Portal-vein infusion
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal-vein infusion (PVI) of fluorouracil
Trial: 8111606
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (16 mg/day)
Trial: 8111606
Drug: Albuterol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (800 micrograms/day)
Trial: 26032655
Drug: Liraglutide (LIRA)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide (LIRA) 1.2 mg QD s.c.
Trial: 26032655
Drug: Roflumilast (ROF)
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast (ROF) 500 mcg QD
Trial: 23609792
Drug: Fructose combined
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose combined with fat (0.5 g/kg body weight fructose, 1 g/kg OFTT cream as fat)
Trial: 23609792
Drug: Fat only
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat only (1 g/kg OFTT cream)
Trial: 23609792
Drug: Glucose (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (0.5 g/kg body weight)
Trial: 23609792
Drug: Fructose (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (0.5 g/kg body weight)
Trial: 21746729
Drug: Moderate-oxygen group
RxNorm normalized name: Corticosteroids, moderately potent (group II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-oxygen group (oxygen titration starting from 100%)
Trial: 19166298
Drug: Purple carrot
RxNorm normalized name: Purple Carrot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple carrot juice containing 76 micromol (65 mg) of total anthocyanins
Trial: 19166298
Drug: Purple carrot
RxNorm normalized name: Purple Carrot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple carrot juice containing 228 micromol (194 mg) of total anthocyanins
Trial: 19166298
Drug: Purple carrot
RxNorm normalized name: Purple Carrot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple carrot juice containing 380 micromol (323 mg) of total anthocyanins
Trial: 16700404
Drug: Liquid multi-vitamin/mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid multi-vitamin/mineral supplement
Trial: 16146036
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment only
Trial: 14559928
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing 150 mg DHEA, 300 mg androstenedione, 750 mg Tribulus terrestris, 625 mg chrysin, 300 mg indole‐3‐carbinol, and 540 mg saw palmetto
Trial: 14559928
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing DHEA, androstenedione and herbal extracts
Trial: 9256120
Drug: Extended triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended triple intrathecal therapy (TIT)
Trial: 1554839
Drug: Ceftriaxone (≤2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (≤2 g IM daily for at least 2 weeks)
Trial: 24237879
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.2 mg·kg(‐1))
Trial: 24237879
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (1 μg·kg(‐1))
Trial: 20038617
Drug: Amdoxovir (AMDX)
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 200 mg b.i.d.
Trial: 20038617
Drug: Amdoxovir (AMDX)
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 300 mg b.i.d.
Trial: 20038617
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) at 200 mg b.i.d.
Trial: 20038617
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) at 300 mg b.i.d.
Trial: 20038617
Drug: Amdoxovir (AMDX)
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amdoxovir (AMDX) at 500 mg b.i.d. + placebo
Trial: 16408674
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination timolol‐dorzolamide
Trial: 12716811
Drug: Electronic reminder
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic reminder plus a letter summarizing the beneficial effects of antiplatelet drugs
Trial: 7581058
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Loratadine daily for 3-4 days
Trial: 7581058
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 30 mg Loratadine
Trial: 7581058
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Loratadine for 5 days
Trial: 6123332
Drug: Estazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam (2 mg)
Trial: 25713293
Drug: ACEI/ARB therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB therapy
Trial: 26194691
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Oral contraceptives (OC)
Trial: 23592752
Drug: 3.4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g/d EPA + DHA supplementation
Trial: 23592752
Drug: 0.85 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.85 g/d EPA + DHA supplementation
Trial: 15289960
Drug: UDCA (8-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (8-10 mg/kg per day)
Trial: 8088691
Drug: nilvadipine 8
RxNorm normalized name: nilvadipine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nilvadipine 8 mg (mornings) and placebo (evenings)
Trial: 8088691
Drug: slow‐release nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow‐release nifedipine 20 mg b.i.d.
Trial: 2654201
Drug: Computer-based instructional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based instructional system in pharmacokinetics
Trial: 2654201
Drug: Conventional teaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional teaching in clinical pharmacokinetics
Trial: 6104497
Drug: Flunitrazepam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.25 mg ml-1 i.v. (average dose 0.014 mg kg-1)
Trial: 6104497
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg ml-1 i.v. (0.29 mg kg-1)
Trial: 26844764
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum albumin levels (mean 3.5 ± 0.5 g/dL)
Trial: 12944341
Drug: Aripiprazole, 30
RxNorm normalized name: Aripiprazole, 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole, 30 mg/day (reduced to 15 mg/day if needed for tolerability)
Trial: 10870361
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of racemic ketamine
Trial: 3519236
Drug: Disopyramide capsules
RxNorm normalized name: disopyramide Oral Capsule
DrugBank: Disopyramide (DB00280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disopyramide capsules (600 mg per day, q.i.d.)
Trial: 3519236
Drug: Disopyramide slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide slow release tablets (600 mg per day, b.i.d.)
Trial: 28850429
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy or manual therapy
Trial: 25239466
Drug: Nevirapine at
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine at 200 mg twice daily
Trial: 25239466
Drug: Efavirenz at
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz at 600 mg daily